Triazine-Based Vanilloid 1 Receptor Open Channel Blockers: Design, Synthesis, Evaluation, and SAR Analysis

The thermosensory transient receptor potential vanilloid 1 channel (TRPV1) is a polymodal receptor activated by physical and chemical stimuli. TRPV1 activity is drastically potentiated by proinflammatory agents released upon tissue damage. Given the pivotal role of TRPV1 in human pain, there is pres...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2011-11, Vol.54 (21), p.7441-7452
Hauptverfasser: Vidal-Mosquera, Miquel, Fernández-Carvajal, Asia, Moure, Alejandra, Valente, Pierluigi, Planells-Cases, Rosa, González-Ros, José M, Bujons, Jordi, Ferrer-Montiel, Antonio, Messeguer, Angel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7452
container_issue 21
container_start_page 7441
container_title Journal of medicinal chemistry
container_volume 54
creator Vidal-Mosquera, Miquel
Fernández-Carvajal, Asia
Moure, Alejandra
Valente, Pierluigi
Planells-Cases, Rosa
González-Ros, José M
Bujons, Jordi
Ferrer-Montiel, Antonio
Messeguer, Angel
description The thermosensory transient receptor potential vanilloid 1 channel (TRPV1) is a polymodal receptor activated by physical and chemical stimuli. TRPV1 activity is drastically potentiated by proinflammatory agents released upon tissue damage. Given the pivotal role of TRPV1 in human pain, there is pressing need for improved TRPV1 antagonists, the development of which will require identification of new pharmacophore scaffolds. Uncompetitive antagonists acting as open-channel blockers might serve as activity-dependent blockers that preferentially modulate the activity of overactive channels, thus displaying fewer side effects than their competitive counterparts. Herein we report the design, synthesis, biological evaluation, and SAR analysis of a family of triazine-based compounds acting as TRPV1 uncompetitive antagonists. We identified the triazine 8aA as a potent, pure antagonist that inhibits TRPV1 channel activity with nanomolar efficacy and strong voltage dependency. It represents a new class of activity-dependent TRPV1 antagonists and may serve as the basis for lead optimization in the development of new analgesics.
doi_str_mv 10.1021/jm200981s
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902338729</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>902338729</sourcerecordid><originalsourceid>FETCH-LOGICAL-a406t-359c2f2b32c5b9b9c63044c796fbecba6b1237581889b4197fd5b3dfd93c26ca3</originalsourceid><addsrcrecordid>eNptkMtKAzEUhoMotlYXvoBkIyJ0NJe5xV1b6wUKhba6HZJMxs6YZsZkRqhPb6TalatzOOfjh_8D4ByjG4wIvq02BCGWYncA-jgiKAhTFB6CPkKEBCQmtAdOnKsQQhQTegx6BLMIxZj2QbWyJf8qjQrG3KkcvnJTal2XOcRwoaRq2trCeaMMnKy5MUrDsa7lu7LuDt4rV76ZIVxuTbv2uxvC6SfXHW_L2p-5yeFytIAjw_XWf0_BUcG1U2e_cwBeHqaryVMwmz8-T0azgIcobgMaMUkKIiiRkWCCyZiiMJQJiwuhpOCx8B2SKMVpykSIWVLkkaB5kTMqSSw5HYCrXW5j649OuTbblE4qrblRdecyhgilaUKYJ693pLS1c1YVWWPLDbfbDKPsx2y2N-vZi9_UTmxUvif_VHrgcgdw6bKq7qyv7f4J-gbumX7O</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902338729</pqid></control><display><type>article</type><title>Triazine-Based Vanilloid 1 Receptor Open Channel Blockers: Design, Synthesis, Evaluation, and SAR Analysis</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Vidal-Mosquera, Miquel ; Fernández-Carvajal, Asia ; Moure, Alejandra ; Valente, Pierluigi ; Planells-Cases, Rosa ; González-Ros, José M ; Bujons, Jordi ; Ferrer-Montiel, Antonio ; Messeguer, Angel</creator><creatorcontrib>Vidal-Mosquera, Miquel ; Fernández-Carvajal, Asia ; Moure, Alejandra ; Valente, Pierluigi ; Planells-Cases, Rosa ; González-Ros, José M ; Bujons, Jordi ; Ferrer-Montiel, Antonio ; Messeguer, Angel</creatorcontrib><description>The thermosensory transient receptor potential vanilloid 1 channel (TRPV1) is a polymodal receptor activated by physical and chemical stimuli. TRPV1 activity is drastically potentiated by proinflammatory agents released upon tissue damage. Given the pivotal role of TRPV1 in human pain, there is pressing need for improved TRPV1 antagonists, the development of which will require identification of new pharmacophore scaffolds. Uncompetitive antagonists acting as open-channel blockers might serve as activity-dependent blockers that preferentially modulate the activity of overactive channels, thus displaying fewer side effects than their competitive counterparts. Herein we report the design, synthesis, biological evaluation, and SAR analysis of a family of triazine-based compounds acting as TRPV1 uncompetitive antagonists. We identified the triazine 8aA as a potent, pure antagonist that inhibits TRPV1 channel activity with nanomolar efficacy and strong voltage dependency. It represents a new class of activity-dependent TRPV1 antagonists and may serve as the basis for lead optimization in the development of new analgesics.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm200981s</identifier><identifier>PMID: 21950613</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Analgesics - chemical synthesis ; Analgesics - chemistry ; Analgesics - pharmacology ; Animals ; Binding Sites ; Drug Design ; Female ; Oocytes - drug effects ; Oocytes - physiology ; Patch-Clamp Techniques ; Rats ; Recombinant Proteins - antagonists &amp; inhibitors ; Structure-Activity Relationship ; Triazines - chemical synthesis ; Triazines - chemistry ; Triazines - pharmacology ; TRPV Cation Channels - antagonists &amp; inhibitors ; Xenopus</subject><ispartof>Journal of medicinal chemistry, 2011-11, Vol.54 (21), p.7441-7452</ispartof><rights>Copyright © 2011 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a406t-359c2f2b32c5b9b9c63044c796fbecba6b1237581889b4197fd5b3dfd93c26ca3</citedby><cites>FETCH-LOGICAL-a406t-359c2f2b32c5b9b9c63044c796fbecba6b1237581889b4197fd5b3dfd93c26ca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm200981s$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm200981s$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21950613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vidal-Mosquera, Miquel</creatorcontrib><creatorcontrib>Fernández-Carvajal, Asia</creatorcontrib><creatorcontrib>Moure, Alejandra</creatorcontrib><creatorcontrib>Valente, Pierluigi</creatorcontrib><creatorcontrib>Planells-Cases, Rosa</creatorcontrib><creatorcontrib>González-Ros, José M</creatorcontrib><creatorcontrib>Bujons, Jordi</creatorcontrib><creatorcontrib>Ferrer-Montiel, Antonio</creatorcontrib><creatorcontrib>Messeguer, Angel</creatorcontrib><title>Triazine-Based Vanilloid 1 Receptor Open Channel Blockers: Design, Synthesis, Evaluation, and SAR Analysis</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The thermosensory transient receptor potential vanilloid 1 channel (TRPV1) is a polymodal receptor activated by physical and chemical stimuli. TRPV1 activity is drastically potentiated by proinflammatory agents released upon tissue damage. Given the pivotal role of TRPV1 in human pain, there is pressing need for improved TRPV1 antagonists, the development of which will require identification of new pharmacophore scaffolds. Uncompetitive antagonists acting as open-channel blockers might serve as activity-dependent blockers that preferentially modulate the activity of overactive channels, thus displaying fewer side effects than their competitive counterparts. Herein we report the design, synthesis, biological evaluation, and SAR analysis of a family of triazine-based compounds acting as TRPV1 uncompetitive antagonists. We identified the triazine 8aA as a potent, pure antagonist that inhibits TRPV1 channel activity with nanomolar efficacy and strong voltage dependency. It represents a new class of activity-dependent TRPV1 antagonists and may serve as the basis for lead optimization in the development of new analgesics.</description><subject>Analgesics - chemical synthesis</subject><subject>Analgesics - chemistry</subject><subject>Analgesics - pharmacology</subject><subject>Animals</subject><subject>Binding Sites</subject><subject>Drug Design</subject><subject>Female</subject><subject>Oocytes - drug effects</subject><subject>Oocytes - physiology</subject><subject>Patch-Clamp Techniques</subject><subject>Rats</subject><subject>Recombinant Proteins - antagonists &amp; inhibitors</subject><subject>Structure-Activity Relationship</subject><subject>Triazines - chemical synthesis</subject><subject>Triazines - chemistry</subject><subject>Triazines - pharmacology</subject><subject>TRPV Cation Channels - antagonists &amp; inhibitors</subject><subject>Xenopus</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkMtKAzEUhoMotlYXvoBkIyJ0NJe5xV1b6wUKhba6HZJMxs6YZsZkRqhPb6TalatzOOfjh_8D4ByjG4wIvq02BCGWYncA-jgiKAhTFB6CPkKEBCQmtAdOnKsQQhQTegx6BLMIxZj2QbWyJf8qjQrG3KkcvnJTal2XOcRwoaRq2trCeaMMnKy5MUrDsa7lu7LuDt4rV76ZIVxuTbv2uxvC6SfXHW_L2p-5yeFytIAjw_XWf0_BUcG1U2e_cwBeHqaryVMwmz8-T0azgIcobgMaMUkKIiiRkWCCyZiiMJQJiwuhpOCx8B2SKMVpykSIWVLkkaB5kTMqSSw5HYCrXW5j649OuTbblE4qrblRdecyhgilaUKYJ693pLS1c1YVWWPLDbfbDKPsx2y2N-vZi9_UTmxUvif_VHrgcgdw6bKq7qyv7f4J-gbumX7O</recordid><startdate>20111110</startdate><enddate>20111110</enddate><creator>Vidal-Mosquera, Miquel</creator><creator>Fernández-Carvajal, Asia</creator><creator>Moure, Alejandra</creator><creator>Valente, Pierluigi</creator><creator>Planells-Cases, Rosa</creator><creator>González-Ros, José M</creator><creator>Bujons, Jordi</creator><creator>Ferrer-Montiel, Antonio</creator><creator>Messeguer, Angel</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111110</creationdate><title>Triazine-Based Vanilloid 1 Receptor Open Channel Blockers: Design, Synthesis, Evaluation, and SAR Analysis</title><author>Vidal-Mosquera, Miquel ; Fernández-Carvajal, Asia ; Moure, Alejandra ; Valente, Pierluigi ; Planells-Cases, Rosa ; González-Ros, José M ; Bujons, Jordi ; Ferrer-Montiel, Antonio ; Messeguer, Angel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a406t-359c2f2b32c5b9b9c63044c796fbecba6b1237581889b4197fd5b3dfd93c26ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Analgesics - chemical synthesis</topic><topic>Analgesics - chemistry</topic><topic>Analgesics - pharmacology</topic><topic>Animals</topic><topic>Binding Sites</topic><topic>Drug Design</topic><topic>Female</topic><topic>Oocytes - drug effects</topic><topic>Oocytes - physiology</topic><topic>Patch-Clamp Techniques</topic><topic>Rats</topic><topic>Recombinant Proteins - antagonists &amp; inhibitors</topic><topic>Structure-Activity Relationship</topic><topic>Triazines - chemical synthesis</topic><topic>Triazines - chemistry</topic><topic>Triazines - pharmacology</topic><topic>TRPV Cation Channels - antagonists &amp; inhibitors</topic><topic>Xenopus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vidal-Mosquera, Miquel</creatorcontrib><creatorcontrib>Fernández-Carvajal, Asia</creatorcontrib><creatorcontrib>Moure, Alejandra</creatorcontrib><creatorcontrib>Valente, Pierluigi</creatorcontrib><creatorcontrib>Planells-Cases, Rosa</creatorcontrib><creatorcontrib>González-Ros, José M</creatorcontrib><creatorcontrib>Bujons, Jordi</creatorcontrib><creatorcontrib>Ferrer-Montiel, Antonio</creatorcontrib><creatorcontrib>Messeguer, Angel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vidal-Mosquera, Miquel</au><au>Fernández-Carvajal, Asia</au><au>Moure, Alejandra</au><au>Valente, Pierluigi</au><au>Planells-Cases, Rosa</au><au>González-Ros, José M</au><au>Bujons, Jordi</au><au>Ferrer-Montiel, Antonio</au><au>Messeguer, Angel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triazine-Based Vanilloid 1 Receptor Open Channel Blockers: Design, Synthesis, Evaluation, and SAR Analysis</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2011-11-10</date><risdate>2011</risdate><volume>54</volume><issue>21</issue><spage>7441</spage><epage>7452</epage><pages>7441-7452</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>The thermosensory transient receptor potential vanilloid 1 channel (TRPV1) is a polymodal receptor activated by physical and chemical stimuli. TRPV1 activity is drastically potentiated by proinflammatory agents released upon tissue damage. Given the pivotal role of TRPV1 in human pain, there is pressing need for improved TRPV1 antagonists, the development of which will require identification of new pharmacophore scaffolds. Uncompetitive antagonists acting as open-channel blockers might serve as activity-dependent blockers that preferentially modulate the activity of overactive channels, thus displaying fewer side effects than their competitive counterparts. Herein we report the design, synthesis, biological evaluation, and SAR analysis of a family of triazine-based compounds acting as TRPV1 uncompetitive antagonists. We identified the triazine 8aA as a potent, pure antagonist that inhibits TRPV1 channel activity with nanomolar efficacy and strong voltage dependency. It represents a new class of activity-dependent TRPV1 antagonists and may serve as the basis for lead optimization in the development of new analgesics.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>21950613</pmid><doi>10.1021/jm200981s</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2011-11, Vol.54 (21), p.7441-7452
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_902338729
source MEDLINE; American Chemical Society Journals
subjects Analgesics - chemical synthesis
Analgesics - chemistry
Analgesics - pharmacology
Animals
Binding Sites
Drug Design
Female
Oocytes - drug effects
Oocytes - physiology
Patch-Clamp Techniques
Rats
Recombinant Proteins - antagonists & inhibitors
Structure-Activity Relationship
Triazines - chemical synthesis
Triazines - chemistry
Triazines - pharmacology
TRPV Cation Channels - antagonists & inhibitors
Xenopus
title Triazine-Based Vanilloid 1 Receptor Open Channel Blockers: Design, Synthesis, Evaluation, and SAR Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A51%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triazine-Based%20Vanilloid%201%20Receptor%20Open%20Channel%20Blockers:%20Design,%20Synthesis,%20Evaluation,%20and%20SAR%20Analysis&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Vidal-Mosquera,%20Miquel&rft.date=2011-11-10&rft.volume=54&rft.issue=21&rft.spage=7441&rft.epage=7452&rft.pages=7441-7452&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm200981s&rft_dat=%3Cproquest_cross%3E902338729%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=902338729&rft_id=info:pmid/21950613&rfr_iscdi=true